{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-007965","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.874856+00:00","generated_at":"2026-05-26T03:31:27.491766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B","bullets":["Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).","GAAP fully diluted EPS $(0.17) vs $1.47 prior; adj. EPS $1.59 (-9% YoY).","Agreements to acquire Life Molecular (Alzheimer's radiodiagnostic) and Evergreen Theragnostics (manufacturing), expected H2 2025.","CMS final 2025 OPPS rule grants separate payment for PYLARIFY and other diagnostic radiopharmaceuticals.","FY 2025 revenue guidance $1.545B-$1.610B; adjusted EPS guidance $7.00-$7.20."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-007965","json":"https://secwatch.observer/filing/0001628280-25-007965.json","markdown":"https://secwatch.observer/filing/0001628280-25-007965.md","text":"https://secwatch.observer/filing/0001628280-25-007965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/0001628280-25-007965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/lnth-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:31:27.491766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}